Health Care, Patient Service was bioAffinity Technologies’s largest product and service line in fiscal 2025, bringing in $4.97M of $6.16M (81%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Health Care, Patient Service | — | $2.20M | $8.18M | $4.97M |
| Histology Service Fees | — | $272.66K | $1.10M | $1.12M |
| Medical Director Fees | — | $19.32K | $66.58K | $68.27K |
| Other Revenues | — | $21.52K | $7.37K | $4.86K |
| Department Of Defense Observational Studies | — | $19.44K | $8.65K | $577 |
| Laboratory Services | $4.80K | — | — | — |
| Diagnostic Research & Development | — | — | $8.65K | $577 |
| Total | $4.80K | $2.53M | $9.37M | $6.16M |
bioAffinity Technologies brought in $6.16M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 34.2% from $9.37M in fiscal 2024. Health Care, Patient Service was the largest at $4.97M (80.7%), ahead of Histology Service Fees at $1.12M (18.1%) and Medical Director Fees at $68.27K (1.1%). The other three lines brought in $6.01K combined.
Compared with fiscal 2024, Histology Service Fees grew 1.2% to $1.12M, while Health Care, Patient Service fell 39.2% to $4.97M.
bioAffinity Technologies began breaking out Health Care, Patient Service in fiscal 2023, Histology Service Fees in fiscal 2023, Medical Director Fees in fiscal 2023 and Other Revenues in fiscal 2023. bioAffinity Technologies stopped reporting Laboratory Services as a separate line after fiscal 2022, when it brought in $4.80K.
bioAffinity Technologies (BIAF) reports its revenue by product and service. In fiscal 2025, Health Care, Patient Service was its largest product and service line, bringing in $4.97M (80.7% of the total), followed by Histology Service Fees at $1.12M (18.1%).
Health Care, Patient Service was bioAffinity Technologies' largest product and service line in fiscal 2025, bringing in $4.97M, or 80.7% of the $6.16M total across its six product and service lines.
Histology Service Fees grew faster than Health Care, Patient Service in fiscal 2025, up 1.2% from $1.10M to $1.12M. Health Care, Patient Service fell 39.2% to $4.97M.
Every figure comes from bioAffinity Technologies' annual financial filings, as reported. Each line keeps the name bioAffinity Technologies gives it, and years follow its fiscal calendar.
bioAffinity Technologies' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.